The present invention relates to methods of using ultrasonic waves in wound treatment. More particularly, the present invention relates to a method of applying a medicament to tissue and delivering ultrasound energy to the medicament and the tissue.
Ultrasonic waves have been widely used in medical applications, including for both diagnostics and therapy as well as for many industrial applications. One diagnostic use of ultrasound waves includes using ultrasonic waves to detect underlying structures in an object or a human tissue. In this procedure, an ultrasonic transducer is placed in contact with the object or tissue via a coupling medium, and high frequency (1-10 MHz) ultrasonic waves are directed into the tissue. Upon contact with various underlying structures, the waves are reflected back to a receiver adjacent the transducer. By comparison of the signals of the ultrasonic wave as sent with the reflected ultrasonic wave as received, an image of the underlying structure can be produced. This technique is particularly useful for identifying boundaries between components of tissue and can be used to detect irregular masses, tumors, and the like.
Two therapeutic medical uses of ultrasound waves include aerosol mist production and contact physiotherapy. Aerosol mist production makes use of a nebulizer or inhaler to produce an aerosol mist for creating a humid environment and delivering drugs to the lungs. Ultrasonic nebulizers operate by the passage of ultrasound waves of sufficient intensity through a liquid, the waves being directed at an air-liquid interface of the liquid at a point underneath or within the liquid. Liquid particles are ejected from the surface of the liquid into the surrounding air following the disintegration of capillary waves produced by the ultrasound energy. This technique can produce a very fine dense fog or mist. Aerosol mists produced by ultrasound are preferred over aerosol mists produced by other methods because a smaller particle size of aerosol can be obtained with the ultrasonic waves. One of the major shortcoming of inhalers and nebulizers is that the aerosol mist cannot be directed to a target area without an air stream, which decreases the efficiency of the ultrasound energy. Ultrasonic sprayers such as those sold by Sonic and Materials Inc., Misonix Inc., Sono-Tek Inc. (see, for example, U.S. Pat. Nos. 4,153,201, 4,655,393, and 5,516,043) operate by passing liquid through a central orifice of an ultrasound instrument-tip. Major disadvantages of these sprayers include non-uniform particle size, heating of liquid flow, and less efficiency of ultrasound waves because of a demolished end (radiation) surface configuration of the tip.
Contact physiotherapy applies ultrasonic waves directly to tissue in an attempt to produce a physical change in the tissue. In conventional ultrasound physiotherapy, an ultrasonic wave contacts the tissue via a coupling medium. Ultrasonic waves produced by the transducer travel through the coupling medium and into the tissue. The coupling medium is typically a bath of liquid, a jelly applied to the surface to be treated, or a water-filled balloon. Conventional techniques provide ultrasonic waves having an intensity of about 0.1 w/cm2 to 3 w/cm2 at a frequency of about 0.8 to 3 Megahertz. The treatment is applied to a skin surface for from about 1 to 30 minutes, two or three times a week. The coupling medium can provide a cooling effect which dissipates some of the energy produced by the ultrasonic transducer.
More importantly, a coupling medium or direct contact between the tissue and ultrasonic transducer is necessary to transmit the ultrasonic waves to the skin surface because ambient air is a relatively poor medium for the propagation of ultrasonic waves.
Several beneficial effects have been reported from contact ultrasound physiotherapy, such as, for example, the following: local improvement of the blood circulation, heating of the tissue, accelerated enzyme activity, muscle relaxation, pain reduction, and enhancement of natural healing processes. Despite these beneficial effects, current techniques of medical physiotherapy using ultrasonic waves are limited by the necessity of providing a direct contact interface between the ultrasonic transducer and the tissue to maintain an effective transmission of the ultrasonic waves from the transducer to the tissue.
The necessity of direct contact with or without a coupling medium makes current methods undesirable. Some tissue conditions may be accessible to contact ultrasound devices but would be impractical for contact ultrasound treatment. For example, fresh or open wounds resulting from trauma, burns or surgical interventions are not suitable for direct contact ultrasound treatment because of the structural nature of the open wound and the painful condition associated with those wounds. Moreover, conventional contact ultrasound may have a destructive effect on these types of open wounds due to the close proximity of an oscillating tip of an ultrasonic transducer relative to the already damaged tissue surface.
It is an object of the invention to provide an improved method and device for treating tissue.
It is also an object of this invention to provide a method and device for treating tissue using ultrasonic waves.
It is a further object of the invention to provide a method and device for delivering drugs, killing bacteria, cleansing a surface, or stimulating healthy tissue cell growth.
It is a yet further object of the invention to treat a wound by spraying the surface of the wound with aerosol mist produced by ultrasonic waves.
It is also an object of the invention to provide a method and device for applying a medicament to the tissue before and/or during delivery of ultrasound energy to the tissue.
These and other objects of the invention will become more apparent from the discussion below.
The present invention provides an apparatus and a method for treating tissue, the apparatus including a generator and a transducer for generating ultrasonic energy and delivering the ultrasonic energy to the biological tissue, from a non-contact distance from the tissue, wherein the generated ultrasonic energy has an intensity capable of penetrating the wound tissue to a beneficial depth to provide a therapeutic effect to the tissue, and of sonicating the medicament for causing the medicament to penetrate the tissue to a beneficial depth to provide a therapeutic effect to the tissue.
The present invention further provides an apparatus and method for generating ultrasonic energy from a non-contact distance from the surface of the wound; and delivering the generated ultrasonic energy to the wound through a gaseous medium (“dry” approach), wherein the generated ultrasonic energy has an intensity capable of penetrating the wound tissue to a beneficial depth to provide a therapeutic effect for decreasing the healing time for the wound.
The present invention further relates to a method and device for spraying (“wet” approach) a wound surface to deliver drugs, kill bacteria, or cleanse a surface by non-contact application of an ultrasound transducer tip. The method applies ultrasonic waves to the wound without requiring direct or indirect (via a traditional coupling medium) contact between the ultrasonic wave transducer and the wound to be sprayed.
The method of the invention comprises producing a directed spray of liquid or powder particles produced by contact of the liquid or powder with a free end surface of an ultrasonic transducer. The ultrasonic waves cause the spray to project outwardly from the distal end surface of the ultrasonic transducer, and the particle spray is directed onto the wound. The particles of the spray provide a medium for propagation of the ultrasonic waves emanating from the distal end surface. According to the method of the present invention a directed particle spray created by low frequency ultrasound waves onto a wound, delivers drug, kills bacteria on the wound, increases blood flow, and removes dirt and other contaminants from the wound's surface (mechanical cleansing).
This method of drug delivery is particularly advantageous on tissues for which local topical application of a drug is desirable but contact with the tissue is to be avoided. Furthermore, the low frequency ultrasound waves used in the method energize the drug and cause penetration of the drug below the surface of the tissue, due to acoustic pressure, microcavitation, etc. Finally, the bacteria killing method is effective when applied to the surface whether the liquid or powder sprayed is a drug (an antiseptic or antibiotic), oil, saline, distilled water, etc.
a is a detailed view of the sprayer illustrated in
b is a detailed view of the sprayer illustrated in
a-7g are each a front cross-sectional view of an ultrasound tip configuration;
a-8i are each an enlarged side view of a different modification of a tip end shape of the ultrasonic sprayer according to the present invention;
a, 9b, and 9c represent cross-sectional, distal, and lateral views, respectively, of the top of an ultrasonic sprayer having a slot, groove, or thread;
The device of the invention that produces a spray is characterized by means for first delivering the liquid to a lateral surface of an ultrasonic transducer tip adjacent to a free end surface such that the liquid is pulled to the free end surface by a vacuum (negative pressure) created by the ultrasound waves on the free end surface of the transducer tip. This effect can be achieved while the angle between the ultrasound instrument and the horizontal is modified up to 90°. (This acoustical effect of delivering liquid from radial side of a tip to the free end was discovered by the inventor of this invention and is called the “Babaev effect”.) This effect occurs when liquid is delivered to the radial surface of a transducer tip about its perimeter, up to 360° about its perimeter, e.g. from the top, side, bottom, etc.
For the above purpose the device preferably has a so-called nozzle constructed from steel (non-disposable) or plastic (disposable) with a suitable valve design. The nozzle allows delivery of liquid to the lateral surface of the transducer tip or directly to the distal side (radiation surface) of the ultrasound transducer, for enabling the transducer to act as a sprayer or atomizer.
One of the major advantages of the invention is the uniformity of the spray particles generated. Because liquid or powder is sprayed from a solid radiation surface, there is substantial uniformity of particle size, about 90% or greater, preferably from about 90 to 96%. It is provided that the distal radiation surface is driven with constant frequency and amplitude to create the spray. It is also provided that the frequency and/or amplitude can be modulated during treatment and that the distal radiation surface is driven with a sinusoidal, rectangular, trapezoidal or triangular wave form.
The step of producing the spray can further include operating the transducer to produce ultrasonic waves having a frequency of from about 18 kHz to 10,000 MHz. Frequencies below 18 kHz, i.e., from about 1 to 18 kHz, can be used as well; however, this lower range is less desirable because this range of sound wave can be uncomfortable to the patient and operator (without ear protection or the like). Frequencies in the range of from about 30 to 100 kHz are preferred, and frequencies of about 40 kHz are most preferred.
The separation distance between the free end surface of the transducer and the surface or object to be sprayed should be a “non-contact” distance of at least 0.1 in. (2.5 mm). Preferably the separation distance is from about 0.1 in. (2.5 mm) to 20 in. (51 cm), more preferably from about 0.1 in. (2.5 mm) to 5 in. (12.7 cm). The liquid or powder to be sprayed can be any appropriate carrier such as water (regular or distilled), saline solution, or oil to be applied to tissue (i.e., biological tissue or non-biological tissue), such as a vegetable, peanut, or canola oil, optionally with a soluble pharmaceutical, e.g., an antibiotic, antiseptic, conditioner, surfactant, emollient, or other active ingredient. The pharmaceutical or the like is preferably present in a concentration sufficiently low to be soluble but high enough to be effective for the intended purpose.
It is within the scope of the invention that the liquid to be sprayed could include a mixture of two or more immiscible liquids or a heterogeneous mixture of a solution and small particles. It is also within the scope of the invention that the spray could include particles, such as powder, and that the liquid in the reservoir could include powder.
The spray produced according to the invention is directed to the object, surface, or tissue to be sprayed for the time and frequency required for accomplishing a particular purpose or treatment. It is believed that a minimum length of spray of at least one second will be required; however, the length or duration of the spray could be from about one second to as much as a minute or more, even 30 minutes. Numerous factors or circumstances, such as, for example, the area to be sprayed (e.g., the size of a wound), the volume rate of spray produced, the concentration of active ingredient, etc., will impact upon the duration and/or frequency of the spraying. Spraying could be required from one or more times daily to as little as two or three times a week or month.
According to the invention, ultrasonic waves are applied to a wound without establishing contact, directly or indirectly, between the ultrasonic transducer and the wound. For example, surfaces of the human body especially suited for treatment in accordance with the method of the present invention include infected and inflammatory situations in open wounds, including trauma or gun shut wounds, fire and chemical burns.
In addition, the method of the present invention is particularly suited to directing a spray into orifices or other body crevices that are difficult to access.
Wound treatment according to the method and apparatus of the present invention has several advantages. First, this method topically applies medicines such as liquid antibiotics to the wound surface without the need to contact infected, inflamed or painful tissue with an instrument. And second, a significant bactericidal effect occurs when a wound surface is sprayed using the method of the present invention.
Moreover, aside from the bactericidal effect and advantages of non-contact treatment, it has been found that using the method of the present invention gave a significant reduction in volume used of liquid medicine used as compared with traditional methods for wound treatment. Similarly, this allows for precise dosage of the sprayed liquid to permit a user, such as a physician, to administer the desired volume of liquid at a desired rate and duration.
It has been found that the method of the present invention decreases healing times for inflammatory and purulent infected wounds from about 1.5 to 3 times faster than traditional methods. This effect results from a bactericidal, blood flow increasing and mechanical cleansing effect of the atomized spray particles, which have ultrasound energy due to the ultrasonic waves. The spray mechanically scrubs the surface of tissue to remove dirt, dead tissue, and purulent buildup on the tissue surface. The mentioned healing effect also results of energized and highly activated antibiotics, and drug penetration into the tissue surface up to 0.5 mm in depth under influence of ultrasound waves.
Additionally, a combination of the low frequency ultrasonic waves and the sonicated medicines (highly activated by ultrasonic energy) destroys the surface bacteria, resulting in a higher disinfecting property of sonicated liquids as compared to ordinarily applied liquids.
The spray of the present method also stimulates healthy cell growth to aid in granulation and epithelization of the healing tissue.
Other applications of the invention can be directed to non-medical uses such as cleansing, sterilizing and coating surfaces of objects and food.
The method of the present invention offers an approach that may re-establish use of some traditional antibiotics and establish a method for fighting bacteria without antibiotics when necessary. The effect of the method of the present invention in highly activating antibiotics may allow some traditional antibiotics to overcome bacteria which have become resistant to that antibiotic. Moreover, independent of the sonication effect of the antibiotics, the low frequency ultrasonic waves applied in accordance with the method of the present invention physically destroy bacteria. The combination of the highly activated antibiotics and of the low frequency ultrasonic waves in accordance with the method of the present invention produce a strong bactericidal effect not found in mere topical application or oral ingestion of antibiotics. This combined effect has been shown to significantly increase the healing of purulent infected wounds.
The present method also provides a system of non-contact drug delivery without use of a compression sprayer system. This simplifies the design of a non-contact drug delivery sprayer and reduces the weight of the sprayer. More importantly, not using compression to propel the atomized particles preserves the ultrasound energy carried by the spray particles.
Delivery of ultrasound energy in accordance with the present invention has been proven to destroy bacteria by action of the ultrasonic waves and by highly activated liquid medicines applied to the tissue.
The method of the present invention provides a method of compressionless non-contact drug delivery.
The invention is better appreciated by making reference to the drawings. In
Valve 34 allows liquid to flow to distal tip 36 as drops or as a continuous flow through gap 46. Valve 34 may be located anywhere, including between reservoir 32 and horn 30. Mechanical movement of the horn 30 in the direction x-x causes liquid to flow to the distal end of radiation surface 36.
a) is a view of the ultrasonic sprayer as used in accordance with the method of the present invention for spraying liquid 48 directed to distal end (radiation surface) 36.
b) is a view of the basic spraying method from side (radial) surface of the tip based on the Babaev effect. In this example, liquid or drug directed to the radiation surface 36 of ultrasound horn 30 becomes sonicated (ultrasonically energized), after being pulled forward by negative pressure (vacuum) created by ultrasound waves and sprays.
As shown in
In the embodiment of the invention shown in
The ultrasound tip or horn may have a regular or irregular lateral cross-section, including circular, oval, elliptical, rectangular, trapezoidal, or a combination thereof. For example,
Radial side surface of the distal end of the tip may have a slot (groove) or thread for liquid to be directed to the radiation surface (
a to 9c are each a view of a radial side surface of the distal end of the tip which has a slot (groove) 19 or thread 20 for liquid to be directed to the radiation surface.
The ultrasonic energy delivered has an intensity capable of providing a therapeutic effect to the wound 40, exerting acoustic pressure and/or causing micro-cavitation. Acoustic pressure refers to a force that can be felt which is exerted through air between the transducer and the tissue being targeted. Microcavitation refers to the formation and pulsation of gas or vapor filled microscopic bubbles in fluids as a result of ultrasonically induced and regularly repeated pressure changes. Advantages to microcavitation include the creation of acoustic streaming which is a steady circulation of fluid in blood vessels induced by ultrasound radiation force.
Preferably, the amplitude achieved by the ultrasonic energy is at least 3 microns and preferably at least 10 microns. Preferably, the frequency used is in the range of 20 kHz-50 MHz, wherein a preferred range is 20-200 kHz, a more preferred range is 20-40 kHz and a most preferred value is 40 kHz, wherein most preferably the lower limit of the frequency used is outside of the human hearing range.
Furthermore, it is advantageous to use a radiation surface 36 having a shape and size selected to achieve delivery of the ultrasonic energy to the wound where the delivered ultrasonic energy has an intensity capable of providing a therapeutic effect to the wound. Selection of the shape and size of the radiation surface 36 in combination with selection of the frequency and amplitude of the ultrasonic energy used is advantageous in achieving delivery of the ultrasonic energy to the wound wherein the ultrasonic energy has an intensity capable of achieving a therapeutic effect to the wound. Preferably, the radiation surface 36 has a relatively large diameter. Actual selection of the diameter is dependent upon the frequency and amplitude selected. Furthermore, the shape of the radiation surface 36 is selected from one of flat, concave, convex, or a combination thereof, and from the configurations shown in
In another embodiment, ultrasonic energy is delivered to the wound without the use of the spray, i.e., the ultrasonic energy is delivered through a medium other than a spray, including a gaseous medium, such as pure air, e.g., ambient air, where the ultrasound transducer 6 is positioned at a non-contact distance from the wound for providing a therapeutic and beneficial effect. The ultrasound waves, even without the use of a spray, destroy surface bacteria and stimulate health cell growth. This method of wound treatment is particularly advantageous on wounds for which contact with the wound should be avoided.
With reference to
In a preferred embodiment of the invention, wherein the ultrasonic energy is delivered to the wound 40′ through a gaseous medium, such as pure air, for achieving a therapeutic effect at the wound 40′, the frequency of the ultrasonic energy generated is selected to be a low frequency. By using a low frequency, a particular or predetermined amplitude for the generated ultrasonic energy is achieved, which is capable of being delivered to the wound with an intensity capable of providing a therapeutic effect to the wound 40′, exerting acoustic pressure and/or causing micro-cavitation. Preferably, the amplitude achieved by the ultrasonic energy is at least 3 microns and preferably at least 10 microns. Preferably, the frequency used is in the range of 20 kHz-50 MHz, wherein a preferred range is 20-200 kHz, a more preferred range is 20-40 kHz and a most preferred value is 40 kHz, wherein most preferably the lower limit of the frequency used is outside of the human hearing range.
Furthermore, it is advantageous to use a radiation surface 36′ having a shape and size selected to achieve delivery of the ultrasonic energy to the wound where the delivered ultrasonic energy has an intensity capable of providing a therapeutic effect to the wound. Selection of the shape and size of the radiation surface 36′ in combination with selection of the frequency and amplitude of the ultrasonic energy used is advantageous in achieving delivery of the ultrasonic energy to the wound wherein the ultrasonic energy has an intensity capable of achieving a therapeutic effect to the wound. Preferably, the perimeter of the radiation surface 36′ is round, rectangular, elliptical, oval, spherical, conical, curved, stepped, with chamfer, etc., or a combination thereof, as shown in
With respect to
With respect to
The embodiment shown in
As described further below, the reservoir may be provided in a device separate from the transducer and the spray may be generated and delivered from another device separate from the transducer, where the separate device may be detached from or attached to the transducer. The spray from the separate device may be a spray generated and delivered by another transducer or by a device that does not use ultrasound energy. Similar to the embodiment described with respect to
The liquid or powder to be sprayed (via the reservoir 32, valve 34 and radiation surface 36 shown in
Another embodiment of a method of the invention includes the step of providing a substance, such as a medicament and herein referred to as medicament, for application of the medicament to tissue, and delivering ultrasound energy to the medicament as it is applied or once it is applied and to the tissue using the embodiment shown in
The medicament may be applied directly to the tissue before the ultrasound energy is delivered to the tissue, and/or during the delivery of the ultrasound energy to the tissue. The medicament may be provided within at least one container from which the medicament is applied to the tissue, where the container is in contact with the tissue, proximate the tissue and/or spaced from the tissue and oriented for directing the medicament at the tissue. The container may have a permeable wall(s) through which the medicament may pass directly to or towards the tissue, manually, automatically and/or mechanically, and/or through which the ultrasound energy may penetrate. The container may be integrated with or separated from the housing of the transducer 6 or 6′. Furthermore, the medicament may be applied below the tissue in addition to or instead of to the surface of the tissue.
The various medicaments and methods for applying the medicament to the tissue may be used sequentially in any combination or sequence in conjunction with application of the ultrasound energy (delivered with and/or without the spray, or sequentially with and without the spray in any sequence). The sequence may include wait periods during which the ultrasound energy is not applied. Specifically, a treatment may include a series of treatments, wherein individual treatments of the series of treatments are selected from the group consisting of: the treatment including the steps of delivering ultrasonic energy from a non-contact distance to the tissue simultaneous with delivery of a spray to the tissue, wherein the ultrasonic energy has an intensity capable of penetrating the tissue to a beneficial depth to provide a therapeutic effect to the tissue and sonicating the spray for causing the medicament to penetrate the tissue to a beneficial depth to provide a therapeutic effect to the tissue; the treatment including the steps of delivering ultrasonic energy from a non-contact distance to the tissue through a substantial expanse of a substantially purely gaseous medium to the tissue, wherein the ultrasonic energy has an intensity capable of penetrating the tissue to a beneficial depth to provide a therapeutic effect to the tissue; and the treatment including the steps of the method of the invention, wherein a different medicament is applied.
Delivery of the ultrasound energy to the medicament and to the tissue energizes the medicament via sonication and causes penetration of the medicament into the tissue for providing an enhanced therapeutic effect to the tissue. Further, the delivery of the ultrasound energy causes exertion of acoustic pressure. The sonicated medicament and the combination of the sonicated medicament and the low frequency ultrasound waves each provide at least advantages similar to the advantages provided by the sonicated spray and the combination of the sonicated spray and low frequency ultrasound waves. Such advantages include increasing potency of the medicament, obtaining more immediate results, decreasing the volume of the medicament used relative to a volume used for a comparable treatment using traditional methods for achieving the same effect, increased precision of dosage of the medicament, re-establishment of traditional antibiotics to which bacteria have become resistant and deeper penetration into the tissue.
The substance may be applied to surfaces other than tissue for non-medical applications, such as cleansing, sterilizing and coating surfaces of objects and food.
The preceding specific embodiments are illustrative of the practice of the invention. It is to be understood, however, that other expedients known to those skilled in the art or disclosed herein, may be employed without departing from the spirit of the invention or the scope of the appended claims.
This application is a Continuation-In-Part of U.S. application Ser. No. 10/409,272 filed on Apr. 7, 2003, by Eilaz Babaev, entitled: ULTRASONIC METHOD AND DEVICE FOR WOUND TREATMENT, which is a Continuation-In-Part of U.S. application Ser. No. 09/669,312 filed on Sep. 25, 2000, by Eilaz Babaev, now U.S. Pat. No. 6,569,099, entitled: ULTRASONIC METHOD AND DEVICE FOR WOUND TREATMENT, the entire contents of both applications are hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
2534046 | Mau | Dec 1950 | A |
2889852 | Dunlap | Jun 1959 | A |
3243122 | Snaper | Mar 1966 | A |
3275059 | McCullough | Sep 1966 | A |
3392916 | Engstrom et al. | Jul 1968 | A |
3433226 | Boyd | Mar 1969 | A |
3504887 | Okerblom | Apr 1970 | A |
3522801 | Robinson | Aug 1970 | A |
3561444 | Boucher | Feb 1971 | A |
3636947 | Balamuth | Jan 1972 | A |
3685634 | Bergling | Aug 1972 | A |
3765606 | Moss et al. | Oct 1973 | A |
3860173 | Sata | Jan 1975 | A |
3952918 | Poitras et al. | Apr 1976 | A |
4052004 | Martin et al. | Oct 1977 | A |
4085893 | Durley, III | Apr 1978 | A |
4153201 | Berger et al. | May 1979 | A |
4192294 | Vasilevsky et al. | Mar 1980 | A |
4251031 | Martin et al. | Feb 1981 | A |
4271705 | Crostack | Jun 1981 | A |
4294407 | Reichl et al. | Oct 1981 | A |
4301093 | Eck | Nov 1981 | A |
4301968 | Berger et al. | Nov 1981 | A |
4309989 | Fahim | Jan 1982 | A |
4319155 | Nakai et al. | Mar 1982 | A |
4334531 | Reichl et al. | Jun 1982 | A |
4352459 | Berger et al. | Oct 1982 | A |
4414202 | Silvetti | Nov 1983 | A |
4428531 | Martin | Jan 1984 | A |
4466571 | Muhlbauer | Aug 1984 | A |
4530360 | Duarte | Jul 1985 | A |
4541564 | Berger et al. | Sep 1985 | A |
4582149 | Slaughter, Jr. | Apr 1986 | A |
4582654 | Karnicky et al. | Apr 1986 | A |
4619400 | Van Der Burgt | Oct 1986 | A |
4642581 | Erickson | Feb 1987 | A |
4655393 | Berger | Apr 1987 | A |
4659014 | Soth et al. | Apr 1987 | A |
4679551 | Anthony | Jul 1987 | A |
4726523 | Kokubo et al. | Feb 1988 | A |
4726525 | Yonekawa et al. | Feb 1988 | A |
4733820 | Endo et al. | Mar 1988 | A |
4756478 | Endo et al. | Jul 1988 | A |
4767402 | Kost et al. | Aug 1988 | A |
4783003 | Hirabayashi et al. | Nov 1988 | A |
4790479 | Matsumoto et al. | Dec 1988 | A |
4793339 | Matsumoto et al. | Dec 1988 | A |
4818697 | Liboff et al. | Apr 1989 | A |
4850534 | Takahashi et al. | Jul 1989 | A |
4877989 | Drews et al. | Oct 1989 | A |
4883045 | Theisz | Nov 1989 | A |
4905671 | Senge et al. | Mar 1990 | A |
4930700 | McKown | Jun 1990 | A |
4941618 | Hildebrand et al. | Jul 1990 | A |
4961885 | Avrahami et al. | Oct 1990 | A |
4982730 | Lewis, Jr. | Jan 1991 | A |
5002059 | Crowley et al. | Mar 1991 | A |
5013241 | von Gutfeld et al. | May 1991 | A |
5040537 | Katakura | Aug 1991 | A |
5063922 | Hakkinen | Nov 1991 | A |
5076266 | Babaev | Dec 1991 | A |
5104042 | McKown | Apr 1992 | A |
5115805 | Bommannan et al. | May 1992 | A |
5134993 | van der Linden et al. | Aug 1992 | A |
5143588 | Liboff et al. | Sep 1992 | A |
5152289 | Viebach et al. | Oct 1992 | A |
5163433 | Kagawa et al. | Nov 1992 | A |
5172692 | Kulow et al. | Dec 1992 | A |
5186162 | Talish et al. | Feb 1993 | A |
5197946 | Tachibana | Mar 1993 | A |
5211160 | Talish et al. | May 1993 | A |
5219401 | Cathignol et al. | Jun 1993 | A |
5231975 | Bommannan et al. | Aug 1993 | A |
5259384 | Kaufman et al. | Nov 1993 | A |
5269291 | Carter | Dec 1993 | A |
5309898 | Kaufman et al. | May 1994 | A |
5314441 | Cusack et al. | May 1994 | A |
5315998 | Tachibana et al. | May 1994 | A |
5316000 | Chapelon et al. | May 1994 | A |
5318014 | Carter | Jun 1994 | A |
5323769 | Bommannan et al. | Jun 1994 | A |
5324255 | Passafaro et al. | Jun 1994 | A |
5345940 | Seward et al. | Sep 1994 | A |
5347998 | Hodson et al. | Sep 1994 | A |
5362309 | Carter | Nov 1994 | A |
5374266 | Kataoka et al. | Dec 1994 | A |
5380411 | Schlief | Jan 1995 | A |
5393296 | Rattner | Feb 1995 | A |
5431663 | Carter | Jul 1995 | A |
5437606 | Tsukamoto | Aug 1995 | A |
5456258 | Kondo et al. | Oct 1995 | A |
5515841 | Robertson et al. | May 1996 | A |
5515842 | Ramseyer et al. | May 1996 | A |
5516043 | Manna et al. | May 1996 | A |
5520166 | Ritson et al. | May 1996 | A |
5520612 | Winder et al. | May 1996 | A |
5527350 | Grove et al. | Jun 1996 | A |
5529572 | Spector | Jun 1996 | A |
5545124 | Krause et al. | Aug 1996 | A |
5547459 | Kaufman et al. | Aug 1996 | A |
5551416 | Stimpson et al. | Sep 1996 | A |
5554172 | Horner et al. | Sep 1996 | A |
5556372 | Talish et al. | Sep 1996 | A |
5573497 | Chapelon | Nov 1996 | A |
5616140 | Prescott | Apr 1997 | A |
5618275 | Bock | Apr 1997 | A |
5626554 | Ryaby et al. | May 1997 | A |
5630828 | Mawhirt et al. | May 1997 | A |
5643179 | Fujimoto | Jul 1997 | A |
5656016 | Ogden | Aug 1997 | A |
5658323 | Miller | Aug 1997 | A |
5664570 | Bishop | Sep 1997 | A |
5688224 | Forkey et al. | Nov 1997 | A |
5699805 | Seward et al. | Dec 1997 | A |
5707402 | Heim | Jan 1998 | A |
5707403 | Grove et al. | Jan 1998 | A |
5725494 | Brisken | Mar 1998 | A |
5730705 | Talish et al. | Mar 1998 | A |
5735811 | Brisken | Apr 1998 | A |
5743863 | Chapelon | Apr 1998 | A |
5752924 | Kaufman et al. | May 1998 | A |
5762616 | Talish | Jun 1998 | A |
5785972 | Tyler | Jul 1998 | A |
5835678 | Li et al. | Nov 1998 | A |
5843139 | Goedeke et al. | Dec 1998 | A |
5879314 | Peterson et al. | Mar 1999 | A |
5879364 | Bromfield et al. | Mar 1999 | A |
5882302 | Driscoll, Jr. et al. | Mar 1999 | A |
5894841 | Voges | Apr 1999 | A |
5895362 | Elmstrom et al. | Apr 1999 | A |
5904659 | Duarte et al. | May 1999 | A |
5947921 | Johnson et al. | Sep 1999 | A |
5960792 | Lloyd et al. | Oct 1999 | A |
5989245 | Prescott | Nov 1999 | A |
6001069 | Tachibana et al. | Dec 1999 | A |
6007499 | Martin et al. | Dec 1999 | A |
6014970 | Irvi et al. | Jan 2000 | A |
6024718 | Chen et al. | Feb 2000 | A |
6026808 | Armer et al. | Feb 2000 | A |
6027495 | Miller | Feb 2000 | A |
6036661 | Schwarze et al. | Mar 2000 | A |
6041253 | Kost et al. | Mar 2000 | A |
6061597 | Rieman et al. | May 2000 | A |
6076519 | Johnson | Jun 2000 | A |
6083159 | Driscoll, Jr. et al. | Jul 2000 | A |
6095141 | Armer et al. | Aug 2000 | A |
6098620 | Lloyd et al. | Aug 2000 | A |
6102298 | Bush et al. | Aug 2000 | A |
6104952 | Tu et al. | Aug 2000 | A |
6106547 | Huei-Jung | Aug 2000 | A |
6113558 | Rosenschein et al. | Sep 2000 | A |
6113570 | Siegel et al. | Sep 2000 | A |
RE36939 | Tachibana et al. | Oct 2000 | E |
6158388 | Wenstrand | Dec 2000 | A |
6158431 | Poole | Dec 2000 | A |
6161536 | Redmon et al. | Dec 2000 | A |
6176839 | Deluis et al. | Jan 2001 | B1 |
6186963 | Schwarze et al. | Feb 2001 | B1 |
6190315 | Kost et al. | Feb 2001 | B1 |
6190336 | Duarte et al. | Feb 2001 | B1 |
6206842 | Tu et al. | Mar 2001 | B1 |
6206843 | Iger et al. | Mar 2001 | B1 |
6231528 | Kaufman et al. | May 2001 | B1 |
6234990 | Rowe et al. | May 2001 | B1 |
6251099 | Kollias et al. | Jun 2001 | B1 |
6254294 | Muhar | Jul 2001 | B1 |
6273864 | Duarte et al. | Aug 2001 | B1 |
6296630 | Altman et al. | Oct 2001 | B1 |
6311573 | Bhardwaj | Nov 2001 | B1 |
6314318 | Petty | Nov 2001 | B1 |
6321109 | Ben-Haim et al. | Nov 2001 | B2 |
6322527 | Talish | Nov 2001 | B1 |
6325769 | Klopotek | Dec 2001 | B1 |
6458109 | Henley et al. | Oct 2002 | B1 |
6478754 | Babaev | Nov 2002 | B1 |
6500133 | Martin et al. | Dec 2002 | B2 |
6533484 | Osei et al. | Mar 2003 | B1 |
6533803 | Babaev | Mar 2003 | B2 |
6559365 | Wilfer | May 2003 | B2 |
6569099 | Babaev | May 2003 | B1 |
6583071 | Weidman et al. | Jun 2003 | B1 |
6601581 | Babaev | Aug 2003 | B1 |
6623444 | Babaev | Sep 2003 | B2 |
6659365 | Gipson et al. | Dec 2003 | B2 |
6663554 | Babaev | Dec 2003 | B2 |
6666431 | McCusker | Dec 2003 | B2 |
6723064 | Babaev | Apr 2004 | B2 |
6732744 | Olshavsky et al. | May 2004 | B2 |
6761729 | Babaev | Jul 2004 | B2 |
6916296 | Soring et al. | Jul 2005 | B2 |
6919296 | Geus et al. | Jul 2005 | B2 |
6960173 | Babaev | Nov 2005 | B2 |
6964647 | Babaev | Nov 2005 | B1 |
7316664 | Kadziauskas et al. | Jan 2008 | B2 |
20020062093 | Soring et al. | May 2002 | A1 |
20020080206 | Lin | Jun 2002 | A1 |
20020138036 | Babaev | Sep 2002 | A1 |
20020177846 | Mulier et al. | Nov 2002 | A1 |
20030023193 | Soring et al. | Jan 2003 | A1 |
20030125660 | Moutafis et al. | Jul 2003 | A1 |
20030195644 | Borders et al. | Oct 2003 | A1 |
20030236560 | Babaev | Dec 2003 | A1 |
20040028552 | Bhardwaj et al. | Feb 2004 | A1 |
20040030254 | Babaev | Feb 2004 | A1 |
20040034982 | Wieber et al. | Feb 2004 | A1 |
20040055376 | Thompson et al. | Mar 2004 | A1 |
20040076175 | Patenaude | Apr 2004 | A1 |
20050075620 | Iger | Apr 2005 | A1 |
20060025716 | Babaev | Feb 2006 | A1 |
20060058710 | Babaev | Mar 2006 | A1 |
20070016110 | Babaev et al. | Jan 2007 | A1 |
20070088245 | Babaev et al. | Apr 2007 | A1 |
20080177221 | Millerd et al. | Jul 2008 | A1 |
20080214965 | Peterson et al. | Sep 2008 | A1 |
20090043248 | Peterson | Feb 2009 | A1 |
Number | Date | Country |
---|---|---|
0 020 844 | Oct 1985 | EP |
0 437 155 | Feb 1990 | EP |
0416106 | Mar 1991 | EP |
0 657 226 | Nov 1994 | EP |
0 619 104 | Mar 2002 | EP |
1 564 009 | Aug 2005 | EP |
2099710 | Dec 1982 | GB |
2101500 | Jan 1983 | GB |
417844 | Jan 1992 | JP |
09135908 | May 1997 | JP |
2000237275 | Sep 2000 | JP |
878268 | Nov 1981 | SU |
910157 | Mar 1982 | SU |
1106485 | Oct 1982 | SU |
1106485 | Aug 1984 | SU |
1827239 | May 1990 | SU |
WO 9406380 | Mar 1994 | WO |
WO 9635383 | Nov 1996 | WO |
9717933 | May 1997 | WO |
WO 0224150 | Jan 2002 | WO |
0224150 | Mar 2002 | WO |
WO 0228350 | Apr 2002 | WO |
02055131 | Jul 2002 | WO |
02060525 | Aug 2002 | WO |
Number | Date | Country | |
---|---|---|---|
20040186384 A1 | Sep 2004 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10409272 | Apr 2003 | US |
Child | 10815384 | US | |
Parent | 09669312 | Sep 2000 | US |
Child | 10409272 | US |